Oppenheimer’s Insights: Synaptics Incorporated (SYNA), Axovant Sciences Ltd (AXON), Syros Pharmaceuticals Inc (SYRS)


Synaptics Incorporated

Top Oppenheimer analyst Andrew Uerkwitz has downgraded his rating on shares of Syros Pharmaceuticals Inc (NASDAQ:SYNA) to Sell – his first Sell rating for the human interface solution developer out of 24 ratings since October 2011.

Uerkwitz referred to four key risks faced by Synaptics, namely share loss of major customers, inability to win high-volume designs among Chinese smartphone original equipment manufacturers (OEMs), pricing deterioration of fingerprint sensor and disrupted operations due to personnel changes.

Uerkwitz gave a $45 price target for Synaptics, significantly lower than the $71.67 average analyst 12-month price target on TipRanks made in the last three months.

Andrew Uerkwitz is a technology-focused analyst with a four-star rating according to TipRanks’ financial accountability engine which places him at #611 out of a total of 4,273 ranked analysts.

Axovant Sciences Ltd

Oppenheimer analyst Jay Olson has reiterated his Buy rating on shares of Axovant Sciences Ltd (NYSE:AXON) based on the potential for Axovant “to deliver the first new FDA-approved symptomatic [Alzheimer] drug in over a decade”.

While there is no cure for Alzheimers, treatments such as those in development at Axovant could temporarily slow the worsening of symptoms and improve the quality of life for patients and their caregivers.

Olson believes that Axovant has been overlooked by investors due to numerous recent failures in Alzheimer clinical trials, particularly in respect of disease-modifying biologics.

His price target for AXON stands at $20.00, lower than the average analyst 12-month price target of $25.83.

Olson has a 50% success rating on TipRanks giving him an average return of 8.2% per recommendation.

Syros Pharmaceuticals Inc

The release of early encouraging data by Syros Pharmaceuticals Inc (NASDAQ:SYRS) from its preclinical breast cancer trial has prompted Oppenheimer analyst Leah R. Cann to reiterate his Buy rating.

The Oppenheimer analyst, who gave a price target of $28, expects Syros to see revenue in 2018 growing to revenue of $510 million in 2021.

According to Cann, data presented on December 10 for Syros’ lead compound, SY-1425, are encouraging for a subset of difficult-to-treat breast cancer patients, which is a large potential market.

However Cann acknowledged the possibility of significant downside to his estimates due to the inherent risks in drug development.

Leah R Cann has a success rate of 67% on TipRanks based on Cann’s recommendations since 2016- giving him a 5.5% average return per recommendation.